EPIX vs. ORGO, TRDA, LRMR, FBLG, TBPH, ESPR, SIGA, URGN, STTK, and PGEN
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Organogenesis (ORGO), Entrada Therapeutics (TRDA), Larimar Therapeutics (LRMR), FibroBiologics (FBLG), Theravance Biopharma (TBPH), Esperion Therapeutics (ESPR), SIGA Technologies (SIGA), UroGen Pharma (URGN), Shattuck Labs (STTK), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Organogenesis (NASDAQ:ORGO) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment.
Organogenesis has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
Organogenesis has a net margin of 1.14% compared to Organogenesis' net margin of 0.00%. ESSA Pharma's return on equity of 1.81% beat Organogenesis' return on equity.
Organogenesis has higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
39.5% of Organogenesis shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Comparatively, 14.7% of ESSA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Organogenesis presently has a consensus price target of $4.83, indicating a potential upside of 75.76%. ESSA Pharma has a consensus price target of $16.50, indicating a potential upside of 81.32%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Organogenesis.
ESSA Pharma received 252 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 76.32% of users gave ESSA Pharma an outperform vote while only 66.21% of users gave Organogenesis an outperform vote.
In the previous week, ESSA Pharma had 3 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for ESSA Pharma and 0 mentions for Organogenesis. ESSA Pharma's average media sentiment score of 1.89 beat Organogenesis' score of 1.35 indicating that Organogenesis is being referred to more favorably in the media.
Summary
Organogenesis beats ESSA Pharma on 9 of the 16 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ESSA Pharma Competitors List
Related Companies and Tools